الفهرس 
Liver Cirrhosis
GynecomastiaOnly 14 pages are availabe for public view
 |  | from | 113 |  |  |
| | | from | 113 | | |
Abstract
The prevalence of gynecomastia in liver cirrhosis is about 44%. There is an increased production of and rostenedione by the adrenal glands, increased aromatisation of and rostenedione to estrogen, loss of clearance of adrenal androgens by the liver, resulting in gynecomastia. Spironolactone is the drug of choice in the treatment of ascites due to liver cirrhosis. Spironolactone induces gynecomastia by decreasing testosterone production, increasing peripheral conversion of testosterone to estradiol, and displacing estradiol from sex hormone-binding globulin.